Journal of Clinical OncologyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

4681 records returned

Call for Clarity in the Reporting of Benefit Associated With Anticancer Therapies [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Booth, Ohorodnyk, Eisenhauer Tags: CORRESPONDENCE Source Type: journals

Consensus Report of the National Cancer Institute Clinical Trials Planning Meeting on Pancreas Cancer Treatment [SPECIAL ARTICLE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer mortality, despite significant improvements in diagnostic imaging and operative mortality rates. The 5-year survival rate remains less than 5% because of microscopic or gross metastatic disease at time of diagnosis. The Clinical Trials Planning Meeting in pancreatic cancer was convened by the National Cancer Institute's Gastrointestinal Cancer Steering Committee to discuss the integration of basic and clinical knowledge in the design of clinical trials in PDAC. Major emphasis was placed on the enhancement of research to identify and validate the ...
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Philip, Mooney, Jaffe, Eckhardt, Moore, Meropol, Emens, O'Reilly, Korc, Ellis, Benedetti, Rothenberg, Willett, Tempero, Lowy, Abbruzzese, Simeone, Hingorani, Berlin, Tepper Tags: Clinical Trials, Growth Factors, Surgery, Radiation, Chemotherapy, Combined Modality, Translational Oncology, Angiogenesis, Signal Transduction, Gastrointestinal, Cancer Biomarkers SPECIAL ARTICLE Source Type: journals

Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology [BIOLOGY OF NEOPLASIA]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Selective kinase inhibitors have emerged as an important class of anticancer agents, with demonstrated clinical efficacy and generally favorable toxicity profiles in several common disease settings where conventional treatments have previously provided only modest benefit. Consequently, a substantial effort is now underway to identify additional therapeutically relevant kinase targets and to develop and test inhibitors of those proteins in a variety of human malignancies. However, it has also become clear that the clinical benefit associated with these agents is typically limited to a subset of treated patients, who in man...
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: McDermott, Settleman Tags: Signal Transduction, Cancer Biomarkers, Oncogenes BIOLOGY OF NEOPLASIA Source Type: journals

Magnetic Resonance Imaging Screening of the Contralateral Breast in Women With Newly Diagnosed Breast Cancer: Systematic Review and Meta-Analysis of Incremental Cancer Detection and Impact on Surgical Management [REVIEW ARTICLE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion MRI detects contralateral lesions in a substantial proportion of women, but does not reliably distinguish benign from malignant findings. Relatively high ICDR may be due to selection bias and/or overdetection. Women must be informed of the uncertain benefit and potential harm, including additional investigations and surgery. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Brennan, Houssami, Lord, Macaskill, Irwig, Dixon, Warren, Ciatto Tags: Diagnosis & Staging REVIEW ARTICLE Source Type: journals

Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer "Unfit" for Cisplatin-Based Chemotherapy: Phase II--Results of EORTC Study 30986 [Genitourinary Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Both combinations are active in this group of unfit patients. However, patients with PS 2 and GFR less than 60 mL/min do not benefit from combination CHT. Alternative treatment modalities should be sought in this subgroup of poor-risk patients. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: De Santis, Bellmunt, Mead, Kerst, Leahy, Maroto, Skoneczna, Marreaud, de Wit, Sylvester Tags: Chemotherapy Genitourinary Cancer Source Type: journals

Prospective Study of Prostate Tumor Angiogenesis and Cancer-Specific Mortality in the Health Professionals Follow-Up Study [Genitourinary Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Aggressive tumors form vessels that are primitive in morphology and function, with consequences for metastases. Vascular size and irregularity reflect the angiogenic potential of prostate cancer and may serve as biomarkers to predict prostate cancer mortality several years after diagnosis. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Mucci, Powolny, Giovannucci, Liao, Kenfield, Shen, Stampfer, Clinton Tags: Prognostic Studies, Risk factors, Epidemiology, Angiogenesis Genitourinary Cancer Source Type: journals

Genetic Abnormalities of the EGFR Pathway in African American Patients With Non-Small-Cell Lung Cancer [Thoracic Oncology]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion African American patients with NSCLC are significantly less likely than white counterparts to harbor activating mutations of EGFR, which suggests that EGFR tyrosine kinase inhibitors (TKIs) are unlikely to yield major remissions in this population. Our findings add to a growing body of evidence that points to genetic heterogeneity of the EGFR pathway in NSCLC among different ethnic groups and that underscores the need for consideration of these differences in the design of future trials of agents that target the EGFR pathway. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Leidner, Fu, Clifford, Hamdan, Jin, Eisenberg, Boggon, Skokan, Franklin, Cappuzzo, Hirsch, Varella-Garcia, Halmos Tags: Epidemiology, Translational Oncology, Growth Factors & Receptor Thoracic Oncology Source Type: journals

Targeted High-Resolution Ultrasound Is Not an Effective Substitute for Sentinel Lymph Node Biopsy in Patients With Primary Cutaneous Melanoma [Melanoma]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion US is not an appropriate substitute for SLN biopsy, but it is of value in preoperative SLN assessment and postoperative monitoring. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Sanki, Uren, Moncrieff, Tran, Scolyer, Lin, Thompson Tags: Non-ASCO Guidelines, Diagnosis & Staging, Ultrasound Melanoma Source Type: journals

Evidence-Based Approach to the Introduction of Positron Emission Tomography in Ontario, Canada [Health Services and Outcomes]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion The proliferation of health technologies is a key driver of increasing health care costs. The Ontario approach to the introduction of PET is a model worth consideration by health systems seeking to ensure that they receive value for money based on a strong evidentiary base when introducing new health technologies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Evans, Laupacis, Gulenchyn, Levin, Levine Tags: Nuclear Medicine Health Services and Outcomes Source Type: journals

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer [Gynecologic Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Cediranib has activity in recurrent EOC, tubal cancer, and peritoneal cancer with predictable toxicities observed with other TKIs. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Matulonis, Berlin, Ivy, Tyburski, Krasner, Zarwan, Berkenblit, Campos, Horowitz, Cannistra, Lee, Lee, Roche, Hill, Whalen, Sullivan, Tran, Humphreys, Penson Tags: Chemotherapy Gynecologic Cancer Source Type: journals

Reply to G. Ferretti et al [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Ludwig, Fleishman Tags: CORRESPONDENCE Source Type: journals

Darbepoetin Alfa and History of Thromboembolic Events [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Ferretti, Felici, Cognetti Tags: CORRESPONDENCE Source Type: journals

Reply to A. Vazquez-Martin et al [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Goodwin, Ligibel, Stambolic Tags: CORRESPONDENCE Source Type: journals

If Mammalian Target of Metformin Indirectly Is Mammalian Target of Rapamycin, Then the Insulin-Like Growth Factor-1 Receptor Axis Will Audit the Efficacy of Metformin in Cancer Clinical Trials [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Vazquez-Martin, Oliveras-Ferraros, Del Barco, Martin-Castillo, Menendez Tags: CORRESPONDENCE Source Type: journals

Reply to F. Puglisi [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Chan Tags: CORRESPONDENCE Source Type: journals

What Does Similarity Mean in Clinical Trials? [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Puglisi Tags: CORRESPONDENCE Source Type: journals

Reply to L. Collette et al and C.M. Tangen et al [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Souhami, Bae, Sandler Tags: CORRESPONDENCE Source Type: journals

Biased Hormonal Therapy Duration Analysis Makes Results Uninterpretable [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Tangen, Goldman, Swanson, Thompson Tags: CORRESPONDENCE Source Type: journals

Selection Bias Is Not a Good Reason for Advising More Than 5 Years of Adjuvant Hormonal Therapy for All Patients With Locally Advanced Prostate Cancer Treated With Radiotherapy [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Collette, Studer Tags: CORRESPONDENCE Source Type: journals

Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue Damage [DIAGNOSIS IN ONCOLOGY]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Theman, Hartzell, Sinha, Polson, Morgan, Demetri, Orgill, George Tags: Chemotherapy, Chemotherapy DIAGNOSIS IN ONCOLOGY Source Type: journals

Spontaneous Remission in a Patient With t(4;14) Translocation Multiple Myeloma [DIAGNOSIS IN ONCOLOGY]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Puig, Trudel, Keats, Li, Braggio, Ahmann, Zeng, Fonseca, Kukreti Tags: Diagnosis & Staging, Biology & Immunology DIAGNOSIS IN ONCOLOGY Source Type: journals

Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Concurrent chemoradiotherapy using multidrug resistance-nonrelated agents and etoposide is a safe and effective treatment for localized nasal NK/T-cell lymphoma and warrants further investigation. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Yamaguchi, Tobinai, Oguchi, Ishizuka, Kobayashi, Isobe, Ishizawa, Maseki, Itoh, Usui, Wasada, Kinoshita, Ohshima, Matsuno, Terauchi, Nawano, Ishikura, Kagami, Hotta, Oshimi Tags: Combined Modality Hematologic Malignancies Source Type: journals

Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Blood or bone marrow blasts ≥ 10%, platelets less than 50 x 109/L, and chromosome 17 aberrations defined AP in patients with MF. Patients in AP should be candidates for intensive therapeutic interventions. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Tam, Kantarjian, Cortes, Lynn, Pierce, Zhou, Keating, Thomas, Verstovsek Tags: Diagnosis & Staging Hematologic Malignancies Source Type: journals

Age-Specific Differences in Oncogenic Pathway Dysregulation and Anthracycline Sensitivity in Patients With Acute Myeloid Leukemia [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion AML in the elderly represents a distinct biologic entity characterized by unique patterns of deregulated signaling pathway variations that contributes to poor survival and anthracycline resistance. These insights should enable development and adjustments of clinically meaningful treatment strategies in the older patient population. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Rao, Valk, Metzeler, Acharya, Tuchman, Stevenson, Rizzieri, Delwel, Buske, Bohlander, Potti, Lowenberg Tags: Epidemiology, Translational Oncology, Hematologic, Other, Gene Expression and Profiling Hematologic Malignancies Source Type: journals

Immuno-Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Our study demonstrates that combining immunohistochemistry with FISH allows construction of an immunoFISH index that significantly predicts survival in elderly DLBCL patients treated with R-CHOP. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Copie-Bergman, Gaulard, Leroy, Briere, Baia, Jais, Salles, Berger, Haioun, Tilly, Emile, Banham, Mounier, Gisselbrecht, Feugier, Coiffier, Molina Tags: Translational Oncology, Protein Profiling, Chromosomal Abnormalities Hematologic Malignancies Source Type: journals

Mobile Phone Use and Risk of Tumors: A Meta-Analysis [Epidemiology]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion The current study found that there is possible evidence linking mobile phone use to an increased risk of tumors from a meta-analysis of low-biased case-control studies. Prospective cohort studies providing a higher level of evidence are needed. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Myung, Ju, McDonnell, Lee, Kazinets, Cheng, Moskowitz Tags: Environmental Risks, Behavioral and Lifestyle Risk Factors Epidemiology Source Type: journals

Racial Differences in Predictors of Intensive End-of-Life Care in Patients With Advanced Cancer [Palliative and Supportive Care]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion White patients with advanced cancer are more likely than black patients with advanced cancer to receive the EOL care they initially prefer. EOL discussions and DNR orders are not associated with care for black patients, highlighting a need to improve communication between black patients and their clinicians. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Loggers, Maciejewski, Paulk, DeSanto-Madeya, Nilsson, Viswanath, Wright, Balboni, Temel, Stieglitz, Block, Prigerson Tags: End of Life, Outcomes Research Palliative and Supportive Care Source Type: journals

Prognostic and Predictive Value of HER2 Extracellular Domain in Metastatic Breast Cancer Treated With Lapatinib and Paclitaxel in a Randomized Phase III Study [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion HER2 bECD does not predict lapatinib benefit in patients with HER2-negative MBC. Changes in ECD status correlates with patient outcome regardless of treatment given. Measuring HER2 ECD is not currently recommended for predicting benefit to lapatinib. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Finn, Gagnon, Di Leo, Press, Arbushites, Koehler Tags: Chemotherapy, Combined Modality, Clinical Trials, Breast Cancer Source Type: journals

Extensive Nodal Disease May Impair Axillary Reverse Mapping in Patients With Breast Cancer [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion In patients with clinically negative axillary nodes, additional study is warranted to assess whether ARM may be used to spare the lymphatics from the arm. In the presence of extensive nodal disease, this technique may identify metastatic blue nodes, which demonstrates that there is not reliable separation of arm and breast lymphatic pathways. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Ponzone, Cont, Maggiorotto, Cassina, Mininanni, Biglia, Sismondi Tags: Diagnosis & Staging, Surgery Breast Cancer Source Type: journals

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion This trial demonstrated that a combined targeted strategy with letrozole and lapatinib significantly enhances PFS and clinical benefit rates in patients with MBC that coexpresses HR and HER2. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Johnston, Pippen, Pivot, Lichinitser, Sadeghi, Dieras, Gomez, Romieu, Manikhas, Kennedy, Press, Maltzman, Florance, O'Rourke, Oliva, Stein, Pegram Tags: Combined Modality Breast Cancer Source Type: journals

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Trastuzumab plus anastrozole improves outcomes for patients with HER2/hormone receptor–copositive MBC compared with anastrozole alone, although adverse events and serious adverse events were more frequent with the combination. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Kaufman, Mackey, Clemens, Bapsy, Vaid, Wardley, Tjulandin, Jahn, Lehle, Feyereislova, Revil, Jones Tags: Chemotherapy, Breast Cancer Source Type: journals

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial [Gastrointestinal Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion These results do not support the routine clinical use of the evaluated polymorphisms, including UGT1A1*28. Further investigation of XRCC1, ERCC2, and GSTP1 as potential predictors of irinotecan toxicity is warranted. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Braun, Richman, Thompson, Daly, Meade, Adlard, Allan, Parmar, Quirke, Seymour Tags: Clinical Trials, Chemotherapy, Translational Oncology, Gastrointestinal, Cancer Biomarkers Gastrointestinal Cancer Source Type: journals

Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer [Gastrointestinal Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion On the basis of our trial and the meta-analysis, GEM-CAP should be considered as one of the standard first-line options in locally advanced and metastatic pancreatic cancer. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Cunningham, Chau, Stocken, Valle, Smith, Steward, Harper, Dunn, Tudur-Smith, West, Falk, Crellin, Adab, Thompson, Leonard, Ostrowski, Eatock, Scheithauer, Herrmann, Neoptolemos Tags: Chemotherapy Gastrointestinal Cancer Source Type: journals

Randomized Phase II Study of Gemcitabine Administered at a Fixed Dose Rate or in Combination With Cisplatin, Docetaxel, or Irinotecan in Patients With Metastatic Pancreatic Cancer: CALGB 89904 [Gastrointestinal Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Gemcitabine/cisplatin, fixed dose rate gemcitabine, gemcitabine/docetaxel, and gemcitabine/irinotecan have similar antitumor activity in metastatic pancreatic cancer. In light of recent negative randomized studies directly comparing several of these regimens with standard gemcitabine, none of these approaches can be recommended for routine use in patients with this disease. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Kulke, Tempero, Niedzwiecki, Hollis, Kindler, Cusnir, Enzinger, Gorsch, Goldberg, Mayer Tags: Chemotherapy Gastrointestinal Cancer Source Type: journals

Dose Finding and Early Efficacy Study of Gemcitabine Plus Capecitabine in Combination With Bevacizumab Plus Erlotinib in Advanced Pancreatic Cancer [Gastrointestinal Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion The maximum-tolerated dose of capecitabine was 1,660 mg/m2. The recommended capecitabine dose in this cytotoxic doublet/biologic doublet regimen is 1,440 mg/m2; this regimen is under evaluation in an ongoing phase II study. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Starling, Watkins, Cunningham, Thomas, Webb, Brown, Thomas, Oates, Chau Tags: Chemotherapy Gastrointestinal Cancer Source Type: journals

What's Race Got to Do With It? [EDITORIALS]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Rhodes, Teno Tags: End of Life, Outcomes Research EDITORIALS Source Type: journals

Axillary Reverse Mapping to Prevent Lymphedema After Breast Cancer Surgery: Defining the Limits of the Concept [EDITORIALS]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Khan Tags: Surgery EDITORIALS Source Type: journals

How to Treat Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Amplified Breast Cancer [EDITORIALS]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Cortes, Baselga Tags: Combined Modality EDITORIALS Source Type: journals

Changing the Paradigm in Conducting Randomized Clinical Studies in Advanced Pancreatic Cancer: An Opportunity for Better Clinical Development [EDITORIALS]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Tabernero, Macarulla Tags: EDITORIALS Source Type: journals

Improving the Methodologic and Ethical Validity of Best Supportive Care Studies in Oncology: Lessons From a Systematic Review [SPECIAL ARTICLE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Lack of rigor in BSC studies has contributed to a generation of research with widespread ethical and methodologic shortcomings. Ad hoc SC and lack of standardization of SC delivery may be sources of systematic bias or error in BSC trials. Rectifying these shortcomings in future studies demands greater vigilance toward these issues by researchers, institutional review boards, editors, and peer reviewers. Given the prevalence of overlooked problems that are later identified, currently open BSC studies should be reevaluated by institutional review boards and researchers to check for ethical and methodologic validit...
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Cherny, Abernethy, Strasser, Sapir, Currow, Zafar Tags: Clinical Trials, Pain Control, Supportive Care, Ethics, Outcomes Research, Quality of Care, Pain Control, Supportive Care, Palliative Care, Chemotherapy SPECIAL ARTICLE Source Type: journals

American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards [ASCO SPECIAL ARTICLE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Standardization of care can reduce the risk of errors, increase efficiency, and provide a framework for best practice. In 2008, the American Society of Clinical Oncology (ASCO) and the Oncology Nursing Society (ONS) invited a broad range of stakeholders to create a set of standards for the administration of chemotherapy to adult patients in the outpatient setting. At the close of a full-day structured workshop, 64 draft standards were proposed. After a formal process of electronic voting and conference calls, 29 draft standards were eliminated, resulting in a final list of 35 draft measures. The proposed set of standards w...
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Jacobson, Polovich, McNiff, LeFebvre, Cummings, Galioto, Bonelli, McCorkle Tags: ASCO SPECIAL ARTICLE Source Type: journals

Histone Deacetylase Inhibitors in Cancer Therapy [REVIEW ARTICLE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Lane, Chabner Tags: Phase I and Clinical Pharmacology REVIEW ARTICLE Source Type: journals

What Does the Medical Profession Mean By "Standard of Care?" [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Strauss, Thomas Tags: CORRESPONDENCE Source Type: journals

Reply to H.E. Eve et al [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Martin, Leonard Tags: CORRESPONDENCE Source Type: journals

Time to Treatment Does Not Influence Overall Survival in Newly Diagnosed Mantle-Cell Lymphoma [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Eve, Furtado, Hamon, Rule Tags: CORRESPONDENCE Source Type: journals

Reply to M. Cavo [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Spencer, Prince, Roberts Tags: CORRESPONDENCE Source Type: journals

Thalidomide Maintenance in Multiple Myeloma: Certainties and Controversies [CORRESPONDENCE]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Cavo, Pantani, Tacchetti, Pallotti, Brioli, Petrucci, Zamagni, Tosi Tags: CORRESPONDENCE Source Type: journals

Coexistence of Leishmaniasis and Hodgkin's Lymphoma in a Lymph Node [DIAGNOSIS IN ONCOLOGY]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Domingues, Menezes, Ostronoff, Calixto, Florencio, Sucupira, Souto-Maior, Ostronoff Tags: Lymphoma DIAGNOSIS IN ONCOLOGY Source Type: journals

Synchronous Advanced Pure Seminoma and Diffuse Large B-Cell Lymphoma: A Case of Multiple Oncologic Dilemmas [DIAGNOSIS IN ONCOLOGY]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: White, DeHaan, Wilson, Zakem, Maatman Tags: Chemotherapy, Therapy, Chemotherapy, Combined Modality DIAGNOSIS IN ONCOLOGY Source Type: journals

Phase II, Randomized, Controlled, Double-Blinded Trial of Weekly Elesclomol Plus Paclitaxel Versus Paclitaxel Alone for Stage IV Metastatic Melanoma [Melanoma]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion E + P resulted in a statistically significant doubling of median PFS, with an acceptable toxicity profile and encouraging OS. A multinational, phase III trial (SYMMETRY) of E + P compared with paclitaxel alone in metastatic melanoma has closed. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: O'Day, Gonzalez, Lawson, Weber, Hutchins, Anderson, Haddad, Kong, Williams, Jacobson Tags: Chemotherapy Melanoma Source Type: journals